FIDE Anti-Doping Regulations
Medical notification form
Competitor's Acceptance of Anti Doping Controls
FIDE Anti-Doping Disciplinary Regulations
T A B L E O F C O N T E N T S
CHAPTER I. General Provisions
CHAPTER II. The Offence of Doping and its Punishment
CHAPTER III. Appeals
CHAPTER IV. World Anti-Doping Agency
CHAPTER V. Accredited Laboratories
CHAPTER VI. Testing Procedures
CHAPTER VII. Entry into force and Modifications of the FIDE Anti-Doping
APPENDIX A. Prohibited Classes of Substances and Prohibited Methods
APPENDIX B. Accredited Laboratories
APPENDIX C. Sampling Procedures in Doping Controls
WHEREAS in furtherance of its role, Federation Internationale Des Echecs (FIDE), in close collaboration with the National Chess Federations (NCFs), the International Olympic Committee (IOC) and the National Olympic Committees (NOCs) dedicates its efforts to ensuring that in chess the spirit of Fair Play prevails, leads the fight against doping in sport and takes measures, the goal of which is to prevent endangering the health of competitors
WHEREAS FIDE's duty to protect the health of competitors and ensure respect for sports ethics leads it to prohibit doping and to oblige competitors to undergo medical tests and examinations, prescribing to such end the sanctions applicable in the event of a violation of the established rules
WHEREAS one of the fundamental objectives of the Olympic Movement is to eliminate completely doping from sport, the adoption by FIDE of the Anti-Doping Disciplinary Regulations reflects the solidarity of the FIDE in the achievement of such goal, and the primary means to achieve this result will be continuing education regarding the ethical values of sport and the dangers, both physical and moral, of doping, these Regulations must be effective to deal with doping cases as they arise
WHEREAS the Anti-Doping Disciplinary Regulations is essentially intended to ensure respect for the ethical concepts implicit in Fair Play, the Olympic Spirit and medical practice and to safeguard the health of competitors
WHEREAS the Anti-Doping Disciplinary Regulations applies to FIDE, its members and Participants in FIDE competitions for which regulations are prescribed in Section D of the FIDE Handbook (FIDE Competitions)
WHEREAS in keeping with the desire of the Olympic Movement to act in the best interests of competitors and other persons concerned whose rights to justice must be safeguarded, the FIDE Anti-Doping Disciplinary Regulations include provisions to enable appeals to be lodged with the Court of Arbitration for Sport against certain decisions rendered in application of such Regulations
Upon the authority of the FIDE General Assembly the FIDE Presidential Board adopts these Regulations with immediate effect
CHAPTER I. GENERAL PROVISIONS
BLOOD DOPING means the administration of blood, red blood cells and related blood products to a competitor, which may be preceded by withdrawal of blood from the competitor who continues to train in such a blood-depleted state
INTENTIONAL DOPING means doping in circumstances where it is established, or may reasonably be presumed, that any Participant acted knowingly or in circumstances amounting to gross negligence
MASKING AGENT means any substance or procedure used for the purpose of or having the effect of altering or suppressing the integrity of urine or other samples used in doping controls
PARTICIPANT means any competitor, coach, trainer, official, medical or para-medical personnel working with or treating competitors participating in or preparing for sports competitions of the Olympic Games, those competitions to which the IOC grants its patronage or support and all competitions organized under the authority, whether direct or delegated, of FIDE, an NCF or NOC including FIDE Competitions
PHARMACEUTICAL, CHEMICAL AND PHYSICAL MANIPULATION means the use of substances and methods, including masking agents which alter, attempt to alter or may reasonably be expected to alter the integrity and validity of urine or other samples used in doping controls, including, without limitation, catheterisation, diuretics, urine substitution and/or tampering, inhibition of renal excretion such as by probenicid and Related Substances and alterations of testosterone and epitestosterone measurements such as epitestosterone application or bromantan administration
PROHIBITED METHOD means any method so described in these Regulations
PROHIBITED SUBSTANCE means any substance so described in these Regulations
RELATED SUBSTANCE means any substance having pharmacological action and/or chemical structure similar to a Prohibited Substance or any other substance referred to in these Regulations
TRAFFICKING shall be deemed to occur when a person, without having expressly received prior authorisation from the competent body,
a.manufactures, extracts, transforms, prepares, stores, expedites, transports, imports, exports, transits, offers subject to payment or free of charge, distributes, sells, exchanges, undertakes the brokerage of, obtains in any form, prescribes, commercialises, makes over, accepts, possesses, holds, buys or acquires in any manner prohibited doping substances;. b.takes any measures to this end, finances such substances or serves as an intermediary for their financing, provokes in any way the consumption or use of such substances, or establishes means of procuring or consuming such substances c.is party to Prohibited Methods
USE means the application, ingestion, inhalation, injection, consumption by any means whatsoever of any Prohibited Substance or Prohibited Method. Use includes counselling the use of, permitting the use of or condoning the use of any Prohibited Substance or Prohibited Method
1. These Regulations applies to all Participants
2. All competitors are subject to doping controls (urine analyses, blood tests and other authorised techniques for detecting prohibited substances or methods)
Article 3 Notwithstanding the obligations of other Participants to comply with the provisions of these Regulations, it is the personal responsibility of any competitor, subject to the provisions of these Regulations, to ensure that he/she does not use or allow the use of any Prohibited Substance or any Prohibited Method
Article 4 The list of Prohibited Substances and Prohibited Methods contained in these Regulations may be changed by the IOC Executive Board upon recommendation by the Council of the World Anti-Doping Agency (WADA) and will come into effect three months, or such shorter delay as shall be specified in cases of medical necessity, after FIDE, the NCFs and the NOCs have been notified, in such manner as shall be determined by WADA.
CHAPTER II. THE OFFENCE OF DOPING AND ITS PUNISHMENT
1. Doping contravenes the fundamental principles of Olympism and sports and medical ethics
2. Doping is forbidden
3. Recommending, proposing, authorizing, condoning or facilitating the use of any substance or method covered by the definition of doping or trafficking therein is also forbidden
Article 2 Doping is
1. the use of an expedient (substance or method) which is potentially harmful to a competitor's health and/or capable of enhancing their performance, or
2. the presence in the competitor's body of a Prohibited Substance or evidence of the use thereof or evidence of the use of a Prohibited Method
1. In a case of doping, the penalties for a first offence are as follows:
a) if the Prohibited Substance used is ephedrine, phenylpropanolamine, pseudoephedrine, caffeine, strychnine or related substances
I) a warning
II) a ban on participation in chess competitions in any capacity whatsoever
III) a fine of up to US$ 100,000
IV) suspension from any competition for a period of one to six months
b) if the Prohibited Substance used is one other than those referred to in paragraph a) above I) a ban on participation in chess competitions in any capacity whatsoever
II) a fine of up to US$ 100,000;.
III) suspension from any competition for a minimum period of two years. However, based on specific, exceptional circumstances to be evaluated in the first instance by the competent FIDE bodies, there may be a provision for a possible modification of the two-year sanction
2. In case of
a) intentional doping
b) the use of a Masking Agent
c) manoeuvres or manipulation that may prevent or distort any test contemplated in these Regulations
d) refusal to undergo any test contemplated in these Regulations
e) doping for which responsibility is imputable to an official or the competitor's entourage
f) complicity or other forms of involvement in an act of doping by members of a medical, pharmaceutical or related profession The sanctions are as follows
a) if the Prohibited Substance used is ephedrine, phenylpropanolamine, pseudoephedrine, caffeine or strychnine and related substances
I) a ban on participation in chess competitions in any capacity whatsoever
II) a fine of up to US$ 100,000
III) suspension from any competition for a period of two to eight years
b) if the Prohibited Substance used is one other than those referred to in paragraph a) above or if it is a repeat offence (a repeat offence being constituted by a further case of doping perpetrated within a period of ten years after the preceding sanction, whatever form it took and whatever the reason for it, became final)
I) a life ban on participation in any chess event in any capacity whatsoever
II) a fine of up to US$ 1,000,000
III) suspension (between four years and life) from all chess competition
3. Any case of doping during a competition automatically leads to invalidation of the result obtained (with all its consequences, including forfeit of any medals and prizes), irrespective of any other sanction that may be applied, subject to the provisions of point 4 of this article
4. In the event that a competitor who is a member of a team is found guilty of doping, the relevant rules of FIDE or its members concerned shall be applied
5. The penalty for an offence committed by a competitor and detected on the occasion of an out-of-competition test as determined by the FIDE Medical Commission shall be the same, mutatis mutandis, and shall take effect from the date the positive result was recorded or the date on which the final judgement further to an appeal is pronounced, whichever is the more recent.
6. The penalties for trafficking in Prohibited Substances are as follows
a) In the event of trafficking in Prohibited Substances the penalty will be suspension for life from participation in any sports organisation, body, activity or event in any capacity whatsoever
In addition, the offence(s) may be reported to the competent administrative and judicial authorities by any interested physical or legal person
Any attempt to perform trafficking shall be penalised in the same manner as the act itself
b) For persons found guilty of trafficking, ignorance of the nature or composition of the Prohibited Substances or the nature or effects of the methods in question does not constitute attenuating circumstances or grounds for exemption from punishment
7. The penalties set out in these Regulations may be applied concurrently insofar as they are compatible and may be accompanied with measures prescribing regular or unannounced tests of the competitor concerned over a specified period of time
1. Intentional doping can be proved by any means whatsoever, including presumption
2. Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definitive conclusions regarding the use of anabolic androgenic steroids
3. An epitestosterone concentration in the urine greater than 200 nanograms per millilitre will be investigated by studies for testosterone
4. The success or failure of the use of a Prohibited Substance or Prohibited Method is not material. It is sufficient that the Prohibited Substance or Prohibited Method was used or attempted for the offence of doping to be considered as consummated.
1. FIDE is entitled to carry out doping control on any competitor in any FIDE Competition
2. The actual conduct of doping control at FIDE Competitions shall be the responsibility of the FIDE Medical Commission except where specifically delegated by the FIDE Medical Commission to a subordinate agency
3. The procedures for Doping Control at FIDE Competitions shall be decided by the FIDE Medical Commission in accordance with the principles contained in Appendix C 4. At all other events (except where doping control is carried out under the rules of another sporting body) the NCF conducting the controls or in whose territory an event is held shall be responsible for conducting doping control and shall adopt the procedures set forth in these Regulations and shall report the results thereof to the FIDE Medical Commission
5. Where doping control results in a positive test on a competitor, who is not a member of the NCF who conducted the doping control, the NCF who conducted the doping control shall, as soon as possible, report the results of such tests to the NCF which normally exercises jurisdiction over such competitor
1. Where a doping offence has taken place in any FIDE Competition disciplinary proceedings will take place in two stages: (i) suspension; (ii) hearing before a FIDE Tribunal comprising not less than three members
2. The competitor shall be suspended from the time that there is evidence that a doping offence has taken place as certified in writing by the FIDE Medical Commission and any prize money or trophy to which that competitor shall be entitled shall be retained by the organiser of the FIDE Competition pending the decision of the FIDE Tribunal on the case in question
3. When a competitor is notified that it is believed that a doping offence has taken place and that he or she is suspended he or she shall be served with a notice informing him or her of his or her right to an oral hearing before a FIDE Tribunal. If the competitor does not request in writing such an oral hearing within 28 days he or she shall be deemed to have waived his or her right to an oral hearing and the FIDE Tribunal shall proceed based on written evidence and submissions only
4. The panel of members of FIDE Tribunals shall initially comprise the members of the FIDE Ethics Commission and as from 2002 shall be appointed by the FIDE General Assembly
5. At the hearing before a FIDE Tribunal the members of the Tribunal shall only find that a doping offence has been committed if they are satisfied that the same has been proved beyond reasonable doubt
6. If a doping offence is proved the FIDE Tribunal shall decide upon the penalty (if any) to be imposed in accordance with these Regulations
CHAPTER III. APPEALS
Any Participant affected by a decision rendered in application of these Regulations by FIDE , the IOC, an NCF, an NOC or other body may appeal from that decision to the Court of Arbitration for Sport, in accordance with the provisions applicable before such court
Accredited laboratories are presumed to have conducted testing and custodial procedures in accordance with prevailing and acceptable standards of scientific practice. This presumption can be rebutted by convincing evidence to the contrary, but the accredited laboratory shall have no onus in the first instance to show that it conducted the procedures other than in accordance with its customary practices
The inclusion of a Prohibited Substance or Prohibited Method in these Regulations is not subject to appeal
Parties appealing from decisions are expected, as is the Court of Arbitration for Sport, to proceed with all due despatch, in the understanding that there must be early certainty with respect to all decisions involving sport
The Court of Arbitration for Sport is entitled to draw inferences from dilatory behaviour on the part of any party appearing before it
The Court of Arbitration for Sport may award costs against a party whose appeal is judged to be vexatious, frivolous, dilatory or otherwise abusive
Participants shall accept the individual or joint obligation to submit disputes concerning the application of these Regulations to the Court of Arbitration for Sport. Such acceptance is presumed by the very fact of participation by the Participants in the Olympic Movement. Any de facto refusal of such acceptance shall result in the Participants being considered as having excluded themselves from the Olympic Movement and thus from FIDE Competitions
CHAPTER IV. WORLD ANTI-DOPING AGENCY
The World Anti-Doping Agency shall have the mission, structure and responsibilities set forth in the documents establishing its existence..
CHAPTER V. ACCREDITED LABORATORIES
For purposes of these Regulations, only those laboratories accredited by WADA are qualified to undertake the detection of the presence of Prohibited Substances and the use of Prohibited Methods
Any laboratory alleging accreditation by WADA shall be required, upon demand, to produce a certificate valid as of the date of the relevant test, procedure or analysis. WADA may also provide evidence as to the existence of such accreditation
The procedure for accreditation of laboratories is provided by WADA
The requirements in reporting is provided by WADA.
CHAPTER VI. TESTING PROCEDURES
The procedures for selection of competitors (other than for out-of-competition tests), collection of samples and sample analysis are contained in Appendix "C" to these Regulations
A result is positive when the "A" sample is positive and any such result may be acted upon for purposes of any competition or out-of-competition test. A Participant may, however, request that the "B" sample be analysed
Should the analysis show the "B" sample not confirm the result of the analysis of the "A" sample
(a) no further sanctions shall apply, but the initial sanction (disqualification) shall nevertheless remain in full force and effect, however
(b) if, without otherwise affecting the competition, it is still possible for the Participant to be reinserted, the Participant may continue to take part in the competition. (For example, if a Participant is entered in more than one event and the second has not commenced, it may be possible to enter the second event. Similarly, depending upon the relevant rules in a team sport, if the team is still in competition, the Participant may be able to take part in future games.)
A FIDE Tribunal constituted in accordance with Article 6 of Chapter II of these Regulations is the only organ competent to rule on the effects of a positive result during a FIDE Competition. It shall request the advice of the FIDE Medical Commission prior to acting on any positive result
In all other competitions organised by or under the authority of FIDE or an NCF, the competent organ of FIDE or such NCF shall be solely responsible for the application of these Regulations in relation to such competitions as well as in relation to all tests which have been conducted out-of-competition..
In competitions organised under the authority of the IOC itself or Continental Associations of NOCs, the Executive Committees of such associations shall be the competent bodies to rule on the effects of a positive result during such competitions
Each body concerned shall advise the FIDE Medical Commission of all positive results and the dispositions made in respect thereof and provide such data in respect of all tests, whether positive results or otherwise, as may be requested by the FIDE Medical Commission
Minor irregularities, which cannot reasonably be considered to have affected the results of otherwise valid tests, shall have no effect on such results. Minor irregularities do not include the chain of custody of the sample, improper sealing of the container(s) in which the sample is stored, failure to request the signature of the competitor or failure to provide the competitor with an opportunity to be present or be represented at the opening and analysis of the "B" sample if analysis of the "B" sample is requested.
At all times, under these regulations, the rules of IOC/WADA shall be applied by the FIDE Medical Commission whenever required.
CHAPTER VII. ENTRY INTO FORCE AND MODIFICATION OF THE FIDE ANTI-DOPING DISCIPLINARY REGULATIONS
These Regulations shall enter into force with effect from 17 August 2001.
Apart from Appendix A as provided in Chapter I Article 4, these Regulations may be modified only by the FIDE Presidential Board, at the instance of or in consultation with the IOC or WADA. The Modifications come into effect within the dates presented by the IOC or WADA or within three months after the NCF's and the NOC's have been notified in such manner as shall be determined by the FIDE Presidential Board..
A N N E X E S
APPENDIX A. PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS
I. PROHIBITED CLASSES OF SUBSTANCES
Prohibited Substances in class (A) include the following examples amineptine, amiphenazole, amphetamines, bromantan, caffeine*, carphedon, cocaine, ephedrines**, fencamfamin, formeterol,***, mesocarb, pentetrazol, pipradrol, salbutamol***, salmeterol***, terbutaline***,... and related substances
* For caffeine the definition of a positive is a concentration in urine greater than12 micrograms per millilitre
** For cathine, the definition of a positive is a concentration in urine greater than 5 micrograms per millilitre. For ephedrine and methylephedrine, the definition of a positive is a concentration in urine greater than 10 micrograms per millilitre. For phenylpropanolamine and pseudoephedrine, the definition of a positive is a concentration in urine greater than 25 micrograms per millilitre.
*** Permitted by inhaler only to prevent and/or treat asthma and exercise-induced asthma.
Written notification by respiratory or team physician that the competitor has asthma and/or exercise induced asthma , is necessary to the relevant medical authority prior to competition. At the Olympic Games, competitors who request permission to inhale a permitted beta agonist will be assessed by an independent medical panel.
NOTE: All imidazole preparations are acceptable for topical use. Vasoconstrictors may be administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological, rectal) of andrenaline and phenylephrine are permitted.
Prohibited Substances in class (B) include the following examples:
buprenorphine, dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine,... and related substances
NOTE: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate, ethylmorphine, pholcodine, propoxyphene and tramadol are permitted.
C. ANABOLIC AGENTS.
Prohibited Substances in class (C) include the following examples:
1. Anabolic androgenic steroids
a.clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol,... and related substances b.androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone*,... and related substances
Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definite conclusions
* The presence of a testosterone (T) to epitestosterone (E) ratio greater than six (6) to one (1) in the urine of a competitor constitutes an offence unless there is evidence that this ratio is due to a physiological or pathological condition, e.g. low epitestosterone excretion, androgen producing tumour, enzyme deficiencies.
In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an investigation before the sample is declared positive. A full report will be written and will include a review of previous tests, subsequent tests and any results of endocrine investigations. In the event that previous tests are not available, the competitor should be tested unannounced at least once per month for three months. The results of these investigations should be included in the report. Failure to co-operate in the investigations will result in declaring the sample positive
2. Beta-2 agonists
bambuterol, clenbuterol, fenoterol, formoterol*, reproterol, salbutamol*, salmeterol*, terbutaline*,... and related substances
*Authorized by inhalation as described in Article (I.A.)
For salbutamol the definition of a positive under the anabolic agent category is a concentration in urine greater than 1000 nanograms per millilitre.
Prohibited substances in class (D) include the following examples:
acetazolamide, bumetanide, chlorthalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannitol*, mersalyl, spironolactone, triamterene,... and related substances
*Prohibited by intravenous injection.
E. PEPTIDE HORMONES, MIMETICS AND ANALOGUES
Prohibited Substances in class (E) include the following examples and their analogues and mimetics:
1.Chorionic Gonadotrophin (hCG) prohibited in males only;
2.Pituitary and synthetic gonadotrophins (LH) prohibited in males only;
3.Corticotrophins (ACTH, tetracosactide);
4.Growth hormone (hGH);
5.Insulin-like Growth Factor (IGF-1);
and all the respective releasing factors and their analogues;
permitted only to treat competitors with certified insulin-dependent diabetes. Written certification of insulin-dependent diabetes must be obtained from an endocrinologist or team physician.
The presence of an abnormal concentration of an endogenous hormone in Class (E) or its diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has been proven to be due to a physiological or pathological condition.
II. PROHIBITED METHODS
The following procedures are prohibited:
1.Blood doping : means the administration of blood, red blood cells and/ or related blood products to a competitor, which may be preceded by withdrawal of blood from the competitor, who continues to train in such a blood-depleted state.
2.Administering artificial oxygen carriers or plasma expanders.
3.Pharmacological, chemical and physical manipulation.
III. CLASSES OF PROHIBITED SUBSTANCES IN CERTAIN CIRCUMSTANCES
No tests shall be carried out for Ethanol unless the FIDE Medical Commission so determine.
No tests shall be carried out for Cannabinoids unless the FIDE Medical Commission so determine.
C. LOCAL ANAESTHETICS
Injectable local anaesthetics are permitted under the following conditions:
1.bupivacaine, lidocaine, mepivacaine, procaine, and related substances, can be used but not cocaine. Vasoconstrictor agents may be used in conjunction with local anaesthetics;
2.only local or intra-articular injections may be administered;
3.only when medically justified.
The systemic use of glucocorticosteroids is prohibited when administered orally, rectally, or by intravenous or intramuscular injection.
Where medically necessary, local and intra-articular injections of glucocorticosteroids are permitted.
The participant must notify to the FIDE Medical Commission before the competition any administration of Glucocorticosteroids.
Prohibited substances in class (E) include the following examples:
acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol, ... and related substances
Tests will be conducted for beta-blockers. Beta-blockers are permitted only to treat pathological conditions necessitating their use. Written notification prior to the particular competition of such a condition by a cardiologist or team physician to the Relevant Medical Authority is necessary
SUMMARY OF URINARY CONCENTRATIONS ABOVE WHICH IOC ACCREDITED LABORATORIES MUST REPORT FINDINGS FOR SPECIFIC SUBSTANCES
caffeine > 12 micrograms / millilitre
carboxy-THC > 15 nanograms / millilitre
cathine > 5 micrograms / milliltre
ephedrine > 10 micrograms / milliltre
epitestosterone > 200 nanograms / millilitre
methylephedrine > 10 micrograms / millilitre
morphine > 1 microgram / millilitre
19-norandrosterone > 2 nanograms/millilitre in males
19-norandrosterone > 5 nanograms/ millilitre in females
phenylpropanolamine > 25 micrograms / millilitre
pseudoephedrine > 25 micrograms / millilitre
(as stimulant) > 100 nanograms / millilitre
(as anabolic agent) 1000 nanograms/ millilitre
T/E ratio > 6.
IV OUT-OF-COMPETITION TESTING.
Out of competition testing shall include the day before the period of competition and also the day after the competition.
Unless specifically requested by the responsible authority, out-of-competition testing is directed solely at prohibited substances in class I.C. (Anabolic Agents), I.D. (Diuretics), I.E. (Peptide Hormones, Mimetics and Analogues), and II (Prohibited Methods).
LIST OF EXAMPLES OF PROHIBITED SUBSTANCES AND PROHIBITED METHODS
This is not an exhaustive list of prohibited substances. Many substances that do not appear on this list are considered prohibited under the term "and related substances". Competitors must ensure that any medicine, supplement, over-the-counter preparation or any other substance they use does not contain any Prohibited Substance.
amineptine, amfepramone, amiphenazole, amphetamine, bambuterol, bromantan, bupropion, caffeine, carphedon, cathine, cocaine, cropropamide, crotethamide, ephedrine, etamivan, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, formoterol, heptaminol, mefenorex, mephentermine, mesocarb, methamphetamine, methoxyphenamine, methylenedioxyamphetamine, methylephedrine, methylphenidate, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phentermine, phenylephrine, phenylpropanolamine,pholedrine, pipradrol, prolintane, propylhexedrine, pseudoephedrine, reproterol, salbutamol, salmeterol, selegiline, strychnine, terbutaline,
buprenorphine, dextromoramide, diamorphine (heroin), hydrocodone, methadone, morphine, pentazocine, pethidine,
androstenediol, androstenedione, bambuterol, boldenone, clenbuterol, clostebol, danazol, dehydrochlormethyltestosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone, drostanolone, fenoterol, fluoxymesterone, formebolone, formoterol, gestrinone, mesterolone, metandienone, metenolone, methandriol, methyltestosterone, mibolerone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, norethandrolone, oxandrolone, oxymesterone, oxymetholone, reproterol, salbutamol, salmeterol, stanozolol, terbutaline, testosterone, trenbolone,
acetazolamide, bendroflumethiazide, bumetanide, canrenone, chlortalidone, ethacrynic acid, furosemide, hydrochlorothiazide, indapamide, mannitol (by intravenous injection), mersalyl, spironolactone, triamterene,
bromantan, diuretics (see above), epitestosterone, probenecid,
PEPTIDE HORMONES, MIMETICS AND ANALOGUES
ACTH, erythropoietin (EPO), hCG*, hGH, insulin, LH*, clomiphene*, cyclofenil*, tamoxifen*, aromatase inhibitors* * prohibited in males only
acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.
APPENDIX B. PROCEDURE FOR ACCREDITATION OF LABORATORIES
Accreditation of a laboratory is granted by the IOC Executive Board, upon the recommendation of WADA
Such accreditation is evidenced by a certificate to such effect signed by the duly authorised representative of WADA. Such certificate shall specify the name of the laboratory and the period for which the certificate shall be valid. Certificates may be issued after the effective date, with retroactive effect
APPENDIX C. SAMPLING PROCEDURES IN DOPING CONTROLS
1. SELECTION OF COMPETITORS
1.1 The procedures which follow are those applicable to FIDE Competitions. In other competitions, as well as in out-of- competition testing, if the FIDE Medical Commission shall determine that out-of-competition testing shall be introduced, the same procedures shall apply, mutatis mutandis
1.2 The FIDE Medical Commission, with the co operation of the NCF concerned and the Organising Committee, shall decide the number of competitors to be subjected to doping control per day in each competition. The available capacity of the laboratory shall be given due consideration
1.3 The FIDE Medical Commission and the representative of the NCF concerned shall determine the number of competitors in each competition to undergo a control, in accordance with the total number agreed upon under paragraph 1.2. In general, these controls will include the first four competitors in the final classification and others chosen at random
1.4 Where a FIDE Competition or other relevant competition is not directly organised by FIDE, before the beginning of the FIDE Competition or other relevant competition the Organising Committee thereof shall inform the FIDE Medical Commission as to the means of selecting those competitors to be checked at random
1.5 Notwithstanding the foregoing, the FIDE Medical Commission shall have the right to request, without justifying the reason therefore, that any competitor undergo a doping control at any time during the relevant competition
1.6 A competitor may be subject to doping control on more than one occasion during the competition
2. COMPETITOR NOTIFICATION AND REGISTRATION FOR DOPING CONTROL
2.1 Immediately after the completion of a game in a competition or after the determination of the final results, the competitors elected for doping control shall be handed a Doping Control Notification by a Doping Control Escort appointed by the FIDE Medical Commission or Organising Committee as the case may be, hereafter referred to as the Escort. The Escort shall also give a Doping Control Pass which provides access to the Doping Control Station to the competitor. From then on the Escort shall be physically beside the competitor and keep the competitor under observation at all times and accompany him or her to the waiting room at the Doping Control Station designated on the Doping Control Notification. The competitor shall report with his/her accreditation card and Doping Control Pass to the Doping Control Station immediately and no later than one hour after receipt of the Doping Control Notification
2.2 A person (a team coach, a doctor or a team-mate of the competitor's delegation) may accompany the competitor to the Doping Control station and may watch all procedures except urination. He or she shall be given a Doping Control Pass by the Escort in order to be able to enter the Doping Control Station. This accompanying person shall possess proper accreditation and shall be a member of the same delegation as the competitor except, in special circumstances, the competitor may choose a member of another NCF
2.3 The Doping Control Notification shall bear the competitor's name, accreditation and starting numbers, if available, and the statement that an accompanying person may be present when the competitor reports for Doping Control. The competitor has to be warned, by clear written notice in the Notification, of the possible consequences should he/she fail to report for the doping control within the given time limit
2.4 Upon presentation of the Doping Control Notification the escort shall enter the time of notification and the competitor shall sign the form. The Doping Control Notification shall be in duplicate, one copy to be kept by the competitor and the original to be returned to the Doping Control Station by the Escort
2.5 Upon arrival at the Doping Control station, the competitor and the accompanying person shall show their Doping Control Passes. The competitor and the escort shall hand the Doping Control Notification to a Doping Control Officer who records the actual time of arrival on the Doping Control Notification, signs it and verifies the identity of the competitor by means of the photo, name and accreditation number on the accreditation card
2.6 The Doping Control Officer shall keep the Doping Control Notification returned by the Escort and return the copy to the competitor
2.7 The actual time of arrival and the identity of the competitor shall then be noted on the Doping Control Official Record
2.8 Should the competitor refuse to sign the Doping Control Notification or fail to report to the Doping Control Station within the time laid down in section 2.1, this fact shall be noted on the Doping Control Official Record. In this case the Doping Control Official record shall be signed by the Doping Control officer and the representative of the FIDE Medical Commission and the representative of the NCF concerned, if present. In addition, the Chairman of the FIDE Medical Commission or his designated Deputy shall be informed immediately by the representative of the FIDE Medical Commission. The Chairman of the FIDE Medical Commission or his designated Deputy shall then decide on the further steps to be taken
2.9 Should the competitor report to the Doping Control Station later than one hour after the time of notification this fact shall be noted on the Doping Control Notification and the Doping Control Official Record. The sampling procedures shall still be carried out, as described below. The representative of the FIDE Medical Commission shall inform the Chairman of the FIDE Medical Commission or his designated Deputy immediately..
2.10 The competitor and the accompanying person shall remain in the Doping Control station waiting room under the supervision of the Doping Control Officer until he or she is called into a consulting area. The competitor and any personal belongings he/she or the accompanying person bring with them (clothing, bags, etc.) may be searched for evidence of manipulation, upon entering and leaving the Doping Control Station
2.11 No photographs, video or tape recordings may be taken inside the Doping Control Station during the doping control procedure
2.12 The original of the Doping Control Notification shall be appended to the Doping Control Official Record
SAMPLE TAKING PROCEDURE
3.1 Only one competitor at a time shall be called into the consulting area
3.2 In addition to the competitor and his/her accompanying person, only the following persons may be present in the consulting area
a representative of the FIDE Medical Commission the Doping Control Medical Officer the Doping Control Technical Officer(s) a representative of the NCF concerned an interpreter
3.3 The Doping Control Station shall contain a supply of
a.disposable collection vessels (contained in bags)
b.disposable urine control kits (contained in bags)
c.disposable partial sample kits (contained in bags)
The specifications of the collection vessel, urine control kit and partial sample kit are to be determined by the FIDE Medical Commission in co-operation with the Organising Committee
3.4 The competitor shall select a collection vessel, visually check that it is empty and clean, proceed to the toilet and urinate a minimum of 75 ml into the collection vessel under the observation of the Doping Control Officer who shall be of the same gender as the competitor
Any clothing preventing the direct observation of the urination shall be removed. The competitor shall return to the consulting area with the collection vessel containing the urine
3.5 If the requested urine volume of 75 ml has been provided, the competitor shall select a urine control kit, open it and place the contents on the table in front of him/her. He/she shall check that the bottles are empty and clean. The competitor shall pour approximately two thirds of the urine from the collection vessel into bottle A and one third into bottle B. A few drops of urine shall remain in the collection vessel. Next, the competitor shall close the two bottles hermetically and check that no leakage occurs. The Doping Control Officer may, with permission of the competitor, assist with the procedures outlined in this paragraph
All remaining urine shall be destroyed immediately after bottles A and B have been sealed
3.6 The Doping Control Officer shall measure the specific gravity and pH of the urine left in collection vessel. The urine pH should not be less than 5 and not greater than 7, and the urine should have a specific gravity of 1.010 or higher. If the sample does not meet these specifications, further samples may be required by the FIDE Medical Commission representative
3.7 The competitor shall declare to the Doping Control Officer any medication and nutritional supplements that he/she may have taken in the preceding three days. The Doping Control Officer shall record this statement on the Doping Control Official Record
3.8 The Doping Control Officer shall check that the code numbers on the bottles and shipping containers are identical, and record the code number on the Doping Control Official Record. The competitor shall then check that the code numbers on the bottles and shipping containers are identical to that recorded on the Doping Control Official Record. The competitor shall place the bottles A and B into the respective shipping containers and close them carefully and the Doping Control Officer shall verify that these are completely closed
3.9 The competitor shall certify, by signing the Doping Control Official Record, that the entire procedure has been performed according to the rules above
Any irregularities identified by the competitor or the accompanying person shall be recorded on the Doping Control Official Record
The Doping Control Official Record shall also be signed by the Doping Control Officer, by the FIDE Medical Commission representative, and, if present, by the accompanying person and the representative of the NC F concerned
The competitor shall be given a copy of the Doping Control Official Record
3.10 If the competitor refuses to give a sample of urine, the possible consequences shall be pointed out to him/her by the FIDE Medical Commission representative. If the competitor still refuses, this fact shall be noted in the Doping Control Official Record. This shall be signed by the Doping Control Officer, the FIDE Medical Commission representative, and, if present, the representative of the NCF concerned. The competitor and the accompanying person may, if they wish, sign the Doping Control Official Record..
The FIDE Medical Commission representative shall be responsible for communicating the refusal to the Chairman of the FIDE Medical Commission or his designated Deputy. 3.11 If the competitor has produced less than the requested urine volume of 75 ml, the competitor shall select a partial sample kit and shall pour the urine from the collection vessel into the bottle. Then the competitor shall close the bottle and check that no leakage occurs
The competitor shall check that the code numbers on the bottle and the partial sample container are the same
Next, the urine volume and code number shall be recorded on the Doping Control Official Record and the competitor shall confirm this by signing the Doping Control Official Record. Finally, the competitor shall insert the bottle into the partial sample container and close it completely. the Doping Control Officer shall verify that this is hermetically closed. The Doping Control Officer may, with the agreement of the competitor, assist with the procedures outlined in this paragraph
The competitor shall return to the waiting room with the partial sample container until he/she is able to deliver urine again. When the competitor is ready to deliver a further urine sample, he/she shall return to the consulting area with the partial sample container, which shall be handed to the doping Control Officer who shall check that the partial sample container is intact and that the code number corresponds to that entered in the Doping Control Official Record
The competitor shall then select a new collection vessel and enter the toilet where he/she shall urinate. The competitor shall return to Consulting Area, open the partial sample container and pour the content into the collection vessel. If the combined urine volumes are less than 75 ml, he/she shall select a new partial sample container and proceed according to the procedure outlined in this paragraph
When the combined volumes total at least 75 ml, the urine sample shall be processed in accordance with the procedure outlined in paragraphs 3.5 to 3.9 above
3.12 The original of the Doping Control Official Record and the annexed Doping Control Notifications shall be placed in an envelope and the copy shall be placed in a separate envelope. After recording on the outside of the envelopes the code numbers of the Doping Control Official Records contained therein and the code number of the transport container seals, the two envelopes shall be closed. The FIDE Medical Commission representative shall be responsible for bringing the envelopes to the Chairman of the FIDE Medical Commission or his designated Deputy The envelopes containing the original and the copies shall be kept closed and placed in separate safes unless their opening is authorised by the Chairman of the FIDE Medical Commission or his designated Deputy
3.13 At the end of each doping control, the shipping containers containing the A and the B samples shall be placed in the respective A and B transport containers. Also, the corresponding laboratory copies for urine samples of the Doping Control Official Record shall be placed in a separate envelope which shall be placed in the transport container containing the A samples. Each transport container shall then be sealed with a numbered seal..
3.14 If one or more of the competitors cannot pass the doping control test at the venue station within the time limits which has been decided by the FIDE Medical Commission and the Organising Committee, the test may be performed at the Competition Polyclinic, at the discretion of the FIDE Medical Commission representative
The competitor shall be accompanied by a Doping Control Officer, the FIDE Medical Commission representative, and the accompanying person if he/she wishes. The FIDE Medical Commission representative and the Doping Control Officer shall ensure that all the necessary material for doping control is available at the Competition Polyclinic
Samples which have been collected shall be transported to the Doping Control Laboratory in accordance with the procedure described in paragraphs 4.1 and 4.2 below
TRANSPORT AND RECEIPT OF THE SAMPLES
4.1 The Doping Control Transport Form shall be completed and given together with the sealed transport containers to the Doping control Courier, hereafter referred to as the Courier, who is in charge of transportation of samples collected at each venue to the Doping Control Laboratory. The records on this form shall include the signature and accreditation number of the Courier, the seal numbers of the transport containers, the venue from which the transport containers have come and the departure time of the Courier
The Doping Control Transport Form shall be signed by the FIDE Medical Commission representative who is on duty and by the Doping Control Officer. The FIDE Medical Commission representative shall be responsible for bringing the original of the Doping Control Transport Form to the Chairman of the FIDE Medical Commission. or his designated Deputy. The courier shall take a copy of the Doping Control Transport Form to be countersigned by the Head of Laboratory or staff member designated by him
4.2 The courier shall take the sealed transport containers to the doping control laboratory without undue delay. At the laboratory, the identity of the courier and seals will be checked by the Head of Laboratory or staff member designated by him, and recorded in the allotted space on the copy of the Doping Control Transport Form. Upon delivery of the transport containers, the Head of Laboratory or staff member designated by him shall record the arrival time of the transport containers, check that the transport containers and their seals are intact, record these facts on the copy of the Doping Control Transport Form, and keep the copy of the Doping Control Transport Form
After unsealing and opening the A transport container at the laboratory, the shipping containers therein shall be examined and the code numbers recorded
The transport container containing the B samples shall be kept sealed at the laboratory under the direct control of the FIDE Medical Commission and be opened only with the authorisation of the Chairman of the FIDE Medical Commission or his designated Deputy
5.1 The analysis of a sample shall be performed as soon as possible after its arrival at the Doping Control Laboratory
5.2 The analysis of a sample shall be carried out in accordance with the methods which have been approved by the FIDE Medical Commission
5.3 In addition to the Head of the Laboratory and the laboratory staff, only the following persons shall be admitted to the laboratory during sample analysis
authorised members of the FIDE Medical Commission persons with special authorisation from the FIDE Medical Commission
5.4 The Head of the Laboratory shall on a daily basis inform the Chairman of the FIDE Medical Commission or his designated Deputy of the results of all the samples analysed
5.5 Should the analysis of the A samples indicate a violation of these Regulations, the Chairman of the FIDE Medical Commission or his designated Deputy shall immediately inform in writing the competitor and the Head of the Delegation of the competitor, or his representative (if any). The B sample will be analysed, if such analysis is requested, at a time determined by the FIDE Medical Commission. Such time shall be recorded in the communication to the competitor and Head of the Delegation of the competitor, or his representative (if any)
5.6 The analysis of B samples shall be carried out in the same laboratory by different laboratory personnel to those who carried out the analysis of the "A" sample (and if this is not possible it shall be carried out by a different laboratory) and under the supervision of a representative of the FIDE Medical Commission. The competitor or delegation in question shall be allowed to send a maximum of three representatives to the laboratory. Should the competitor delegation not be present at the laboratory, at the time indicated, the representative of the FIDE Medical Commission may decide to proceed to the B analysis. The Head of the Laboratory shall inform the Chairman of the FIDE Medical Commission or his designated Deputy of the result of this analysis, which shall be regarded as final. The Chairman of the FIDE Medical Commission or his designated Deputy shall be supplied with appropriate documentation of the results by the Head of the Laboratory
5.7 Should the result of the B sample not confirm the result of A analysis, the case is subject to any decisions made in the context of the competition which may no longer be reversed, considered as negative
The Chairman of the FIDE Medical Commission shall immediately inform the competitor and the Head of Delegation of the competitor, or his representative (if any)
5.8 Should the result of the A sample be positive, the Chairman of the FIDE Medical Commission or his designated Deputy shall then call a meeting of the FIDE Medical Commission, to which the competitor, not more than three representatives of the delegation concerned and a representative from the International Federation concerned shall be invited. Following this meeting, the FIDE Medical Commission shall make a recommendation to the FIDE Tribunal appointed pursuant to Article 6 of Chapter II which shall be responsible for dealing with the case in accordance with Chapter II of these Regulations
5.9 The Chairman of the FIDE Medical Commission or his designated Deputy shall designate a representative of the FIDE Medical Commission to remain at the doping control laboratory following the end of the competition until completion of the analyses and the sending of the results to the Chairman of the FIDE Medical Commission or his designated Deputy
DELEGATION OF RESPONSIBILITIES
The Chairman of the FIDE Medical Commission or his designated Deputy may delegate his responsibilities to such person or persons as he may designate, at his discretion, from time to time
DOPING CONTROL LABORATORY: Relevant IOC accredited laboratory
DOPING CONTROL NOTIFICATION: A form used for keeping a record of the notification procedure
The Doping Control Notification consists of one original and one copy. The original is given to the Chairman of the FIDE Medical Commission or his designated Deputy. The copy is given to the competitor
DOPING CONTROL OFFICIAL RECORD: A form used for keeping a record of the sample taking procedure. The Doping Control Official Record consists of one original and three copies. The original and one copy are given to the Chairman of the FIDE Medical Commission or his designated Deputy. One copy is kept by the competitor and one copy is sent to the laboratory with the urine sample
DOPING CONTROL OFFICER: Doping Control Medical Officer and Doping Control Technical Officer
DOPING CONTROL MEDICAL OFFICER: A medical doctor who is in charge of and responsible for the Doping Control Station. He is answerable to the Chief Medical Officer of the relevant organising committee
DOPING CONTROL TECHNICAL OFFICER: A person who supervises notification and sample taking procedures. The Doping Control Technical Officers take instructions from the Doping Control Medical Officer
ESCORT: A person responsible for delivering the Doping Control Notification to the selected competitor. This person will also accompany the competitor and watch him or her continuously until they reach the Doping Control Station. The Escorts take instructions from the Doping Control Medical Officer
COURIER: Officer in charge of transportation of samples collected at each venue and taken to the Doping Control Laboratory.
FIDE MEDICAL COMMISSION REPRESENTATIVE: person appointed by the Chairman of the FIDE Medical Commission or his designated Deputy. His responsibility is to supervise the sample taking procedure and ensure that it is carried out according to these Regulations
PARTIAL SAMPLE KIT: A plastic bag containing one urine bottle with cap and one black shipping container. The partial sample kit is used for temporary storage of the urine sample when the total urine volume produced by the competitor is less than the requested quantity of 75 ml
TRANSPORT CONTAINER: A bag into which the shipping containers can be placed for transportation to the laboratory. It is sealed with a plastic seal
URINE CONTROL KIT: A plastic bag containing two urine bottles with caps, one marked "A" and one "B" and two shipping containers, one green and one yellow. The shipping containers are plastic containers for shipping and storing the urine bottles and are sealed with a system that ensures that they cannot be tampered with. The green shipping container is used for sample A and the yellow shipping container for sample B. The bottle labels show the minimum levels of urine they must contain and the FIDE logo and code number. The shipping containers are embossed with the FIDE logo and a code number, the number being the same as the bottle labels
DOPING CONTROL STATION: Area of restricted access (waiting room and consulting area)
CONSULTING AREA: A large room divided into several booths
DISPOSABLE MATERIAL: This should be checked prior to the competition for contamination and substances which might interfere with the analysis.
My Home Page